Full Breakdown
Decline in Benzodiazepine Prescriptions Amid Ongoing Overdose Risks
3/2/2026, 10:04:59 PM
Overview of Benzodiazepine Use in the U.S.
A recent study published in the *Journal of Clinical Psychiatry* indicates a decline in benzodiazepine prescriptions in the United States, particularly among middle-aged adults and seniors. The research, led by Dr. Mark Olfson from Columbia University, analyzed data from over 104,000 adults participating in a federal health survey between 2018 and 2022. The findings revealed that benzodiazepine use decreased from 4.7% in 2018 to 3.4% in 2022, with a more significant drop among individuals aged 56 and older, from 7.2% to 4.7%.
Co-Prescribing and Overdose Risks
Despite the overall decline in prescriptions, the study highlights a concerning trend regarding co-prescribing practices. Nearly 42% of individuals using benzodiazepines were also prescribed another central nervous system depressant, which heightens the risk of overdose. This co-prescribing was notably prevalent among adults aged 36 to 55 (45%) and those aged 56 and older (43%), compared to 30% among younger adults aged 18 to 35. The data also indicated that a significant portion of those at risk were in poor health; 72% of individuals in fair to poor health were prescribed potentially dangerous combinations, as were 63% of those experiencing serious psychological distress.
Historical Context of Benzodiazepine Use
Benzodiazepines, which include medications such as Xanax (alprazolam), Valium (diazepam), Halcion (triazolam), and Klonopin (clonazepam), are commonly prescribed for anxiety, seizures, sleep disorders, and alcohol dependence. However, their use has been controversial due to associated risks, including withdrawal symptoms, cognitive impairment, and overdose. Between 2000 and 2019, benzodiazepine-related overdose deaths increased sixfold, from just under 0.5 deaths per 100,000 adults to nearly 3 per 100,000.
Official Statements & Responses
Dr. Mark Olfson emphasized the need for careful monitoring of benzodiazepine prescriptions, particularly given the high rate of co-prescribing with other depressants. He stated, “Although benzodiazepine use is declining in U.S. outpatient care, the high rate of co-prescribing underscores the need for careful monitoring.” This sentiment reflects the ongoing concern among health professionals regarding the safety of benzodiazepine use in conjunction with other medications.
Criticism & Opposition
Critics of benzodiazepine prescribing practices argue that the risks associated with these medications, particularly when combined with other central nervous system depressants, warrant stricter guidelines and monitoring. The increasing rates of overdose deaths linked to benzodiazepines have prompted calls for more comprehensive strategies to manage their use in clinical settings.
Conflicting Reports & Gaps
While the study indicates a decline in benzodiazepine prescriptions, it does not provide a comprehensive analysis of the reasons behind this trend or the potential impact on patients who may require these medications for legitimate medical conditions. Further research is needed to explore the implications of reduced access to benzodiazepines for those in need.
Verbatim Quotes
- “Although benzodiazepine use is declining in U.S. outpatient care, the high rate of co-prescribing with other central nervous system depressants underscores the need for careful monitoring,” — Dr. Mark Olfson, Professor of Epidemiology, Columbia University.
